Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Neuraxpharm

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual BoothDevelopment, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Permira Funds

            Deal Size: $1,880.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 22, 2020

            Details:

            The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.

            Virtual BoothDevelopment, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.

            Contact the Supplier

            Lead Product(s): Cannabis products

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Panaxia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 22, 2020

            Details:

            The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.